Primaquine

證據等級: L5

預測適應症: 8 個

Primaquine: From Malaria to Pneumocystosis (Pneumocystis Pneumonia)

One-Sentence Summary

Primaquine is an 8-aminoquinoline antimalarial, established for over 70 years as the only agent capable of radical cure of P. vivax/P. ovale malaria and of blocking P. falciparum transmission. The evidence in this pack supports its established use in combination with clindamycin for Pneumocystis jirovecii pneumonia (PCP), with 6 clinical trials (including a 290-patient Phase III RCT) and 19 publications — spanning guidelines, systematic reviews, and decades of clinical use — supporting this direction. Note: this pack also lists malaria itself (rank 7) as a “predicted” indication; given the depth of evidence, this is almost certainly a data-gap artifact (see Conclusion) rather than a genuine repurposing signal.

Quick Overview

Item	Content
Original Indication	Malaria (radical cure of P. vivax/P. ovale, transmission-blocking in P. falciparum) — established via literature evidence (FDA-licensed since 1952, PMID 22152065); not available from structured regulatory fields (data gap)
Predicted New Indication	Pneumocystosis (Pneumocystis jirovecii pneumonia, PCP) — as second-line therapy in combination with clindamycin
TxGNN Prediction Score	99.32%
Evidence Level	L1
US Market Status	Not marketed (per this dataset) — flagged as a likely data gap, see below
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed structured mechanism-of-action data is not available (data gap DG002). Based on the clinical and literature evidence contained in this pack, Primaquine is an 8-aminoquinoline whose active oxidative metabolites disrupt mitochondrial and redox function in susceptible organisms. This mechanism underlies its well-established antimalarial activity against Plasmodium liver hypnozoites and gametocytes.

The same oxidative/mitochondrial-disruption mechanism has been shown, since at least 1988 (PMID 3261959), to be active against Pneumocystis jirovecii — historically classified as a protozoan and now reclassified as a fungus, but sharing mitochondrial vulnerability to 8-aminoquinoline oxidative stress. When combined with clindamycin (which independently inhibits protein synthesis), the combination produces a well-documented synergistic effect against Pneumocystis.

Clindamycin–primaquine is not a novel hypothesis: it is an established, guideline-recognized second-line regimen for mild-to-moderate PCP in patients intolerant of or unresponsive to first-line trimethoprim-sulfamethoxazole (TMP-SMX), supported by a completed 290-patient Phase III RCT (NCT00000640) and referenced in the 2016 ECIL guidelines (PMID 27550993) and a 2025 network meta-analysis (PMID 39732393). The TxGNN score here largely reflects a well-established clinical practice rather than a novel mechanistic hypothesis.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00000640	Phase 3	Completed	290	Comparative RCT: dapsone/trimethoprim vs. clindamycin/primaquine vs. TMP-SMX for mild-to-moderate PCP in AIDS patients
NCT00000717	N/A	Completed	50	Safety and efficacy of clindamycin + primaquine for mild-moderate PCP
NCT04328688	N/A	Completed	30	Clindamycin-TMP/SMX for PCP after solid organ transplant; clindamycin-primaquine referenced as second-line alternative
NCT07357103	Phase 4	Not yet recruiting	416	SPIRIT-PCP platform trial positioning second-line PCP therapies, likely to include clindamycin/primaquine arm
NCT06691321	N/A	Recruiting	60	Caspofungin for PCP in HIV/AIDS — same disease domain, not a direct primaquine test
NCT00636935	Phase 4	Withdrawn	0	Oral corticosteroids in mild PCP — does not test primaquine directly

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27550993	2016	Guideline	J Antimicrob Chemother	ECIL guidelines for PCP treatment in non-HIV haematology patients; lists clindamycin-primaquine as an alternative regimen
39732393	2025	Systematic Review/Meta-analysis	Clin Microbiol Infect	Network meta-analysis of RCTs comparing PCP treatment regimens in people with HIV
3261959	1988	In vitro/In vivo	Antimicrob Agents Chemother	Foundational study: clindamycin + primaquine effective against Pneumocystis carinii in vitro and in vivo
2060532	1991	Clinical study	Eur J Clin Microbiol Infect Dis	Clindamycin + primaquine as primary treatment for mild/moderate PCP in 36 AIDS patients; 91% response rate
8086551	1994	Clinical trial (ACTG 044)	Clin Infect Dis	Prospective safety/efficacy study of clindamycin + primaquine for mild-moderate PCP
2321069	1990	Clinical study	South Med J	Clindamycin/primaquine therapy and secondary prophylaxis against PCP in AIDS patients
36969352	2023	Review	Avicenna J Med	Management of PCP in HIV and non-HIV immunocompromised patients
33870843	2021	Review	Expert Opin Pharmacother	Pneumocystis jirovecii: prevention and treatment overview
36160421	2022	Review (safety)	Front Pharmacol	PCP medication selection in G6PD-deficient patients — directly relevant safety guardrail
41552137	2025	Case report	Cureus	Primaquine-induced methemoglobinemia during empiric PCP treatment in an immunosuppressed transplant patient

US Market Information

No marketing authorization records are present in this dataset (total_licenses = 0). This is inconsistent with the extensive real-world clinical trial and literature evidence showing Primaquine has been an FDA-licensed antimalarial since 1952 and is in routine clinical use worldwide — this discrepancy is flagged as a data gap requiring resolution (see Conclusion) rather than treated as evidence of “unapproved” status.

Safety Considerations

Official structured safety fields (key warnings, contraindications, drug interactions) are unavailable in this pack (data gap DG001, severity: Blocking). Please refer to the package insert for authoritative safety information.

For transparency, the following safety signals recur consistently across the literature evidence reviewed above and should inform any guardrail design:

G6PD deficiency / hemolysis risk: Primaquine’s oxidative metabolites can cause clinically significant hemolytic anemia in glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals (PMID 36160421, 25943156). G6PD testing prior to use is standard practice in malaria treatment guidelines.
Methemoglobinemia: Reported both alone and in combination with dapsone, including in immunosuppressed patients treated for PCP (PMID 8757424, 41552137).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Clindamycin-primaquine for PCP is supported by L1-level evidence — a completed Phase III RCT, an international treatment guideline, and nearly four decades of clinical use in HIV and non-HIV immunocompromised patients — but the missing TFDA/official label data (DG001, Blocking) prevents this pack from completing a formal S1 safety review, and the known G6PD/hemolysis and methemoglobinemia risks require explicit protocol-level guardrails before clinical advancement.

To proceed, the following is needed:

Resolve DG001: obtain official product label (warnings, contraindications, DDI) to complete S1 safety review
Resolve DG002: confirm structured MOA data via DrugBank API
Reconcile the “Not marketed / 0 licenses” regulatory status against the extensive documented approved use of Primaquine — this is likely a data collection gap rather than a true market-status finding, and should be corrected before this candidate is presented externally
Mandatory G6PD deficiency screening protocol if advancing to clinical evaluation
Separately re-evaluate rank 7 (malaria) as a data-integrity issue rather than a genuine repurposing candidate, since it is Primaquine’s original, already-established indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.